Last edition
News about Clinical Trials
Biohaven Completes Enrollment in Phase II Trial of Taldefgrobep for Obesity
Biohaven finishes enrollment in Phase II study of taldefgrobep, a novel therapy targeting fat loss and muscle gain, with topline data expected in the second half of 2026.
Clinical Trials | 21/03/2026 | By News Bureau | 261
Lilly's Retatrutide Shows Strong A1C, Weight Reduction in Phase-III Diabetes Trial
Eli Lilly’s Retatrutide reduced A1C by up to two percent and delivered average weight loss of 36.6 lbs in its phase-III TRANSCEND-T2D-1 trial, with continued weight reduction observed through 40 weeks in type-II diabetes mellitus patients.
Clinical Trials | 20/03/2026 | By News Bureau | 151
Sobi Presents Positive Phase IIa Data for Gamifant in Interferon-Driven Sepsis
Sobi reports encouraging Phase IIa EMBRACE study results showing potential of Gamifant in interferon-gamma-driven sepsis, supporting precision medicine approaches in treating high-risk patients.
Clinical Trials | 19/03/2026 | By News Bureau | 108
GentiBio Doses First Patient in Phase I Trial of Novel Cell Therapy for Type 1 Diabetes
GentiBio initiates Phase I POLARIS trial of GNTI-122, an engineered Treg therapy aimed at preserving insulin production and reducing lifelong insulin dependence in newly diagnosed type 1 diabetes patients.
Clinical Trials | 19/03/2026 | By News Bureau | 126
BioVersys AG receives US Food and Drug Administration nod to include US patients in Phase III BV100 trial targeting drug-resistant pneumonia, marking progress in combating deadly hospital infections globally.
Clinical Trials | 18/03/2026 | By News Bureau
EBGLYSS Achieves Phase-III Success in Children with Moderate-to-Severe Atopic Dermatitis
In phase-III ADorable-1 study, EBGLYSS demonstrated strong efficacy in paediatric atopic dermatitis. The treatment also showed meaningful gains in higher efficacy endpoints and itch relief, alongside a safety profile consistent with previous studies and no reported injection site pain.
Clinical Trials | 17/03/2026 | By Akanki
UK Health Security Agency and Stablepharma report positive Phase I results for SPVX02, a fridge-free Tetanus and Diphtheria vaccine stable at 30°C for 24 months.
Clinical Trials | 17/03/2026 | By News Bureau
Merck Showcases New Cardio-Pulmonary Data at ACC.26
Merck presented late-breaking data from phase-III and phase-II trials at ACC.26, highlighting advances in its cardio-pulmonary pipeline, including an investigational oral PCSK9 inhibitor and therapies for pulmonary hypertension.
Clinical Trials | 17/03/2026 | By News Bureau | 136
Meiji Seika Pharma Initiates Phase I Trial of ME3241 PD-1 Agonist Antibody for Autoimmune Diseases
Meiji Seika Pharma Co., Ltd. has launched a Phase I clinical trial of ME3241, a novel anti-PD-1 agonist antibody developed with Foundation for Biomedical Research and Innovation at Kobe for autoimmune disease treatment.
Clinical Trials | 16/03/2026 | By News Bureau | 168
Immutep Limited will discontinue the Phase III TACTI-004 trial of eftilagimod alfa in first-line Non-Small Cell Lung Cancer after an interim analysis by the monitoring committee found the study unlikely to meet endpoints.
Clinical Trials | 16/03/2026 | By News Bureau | 110
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy